sr 48692 has been researched along with quinazolines in 1 studies
| Studies (sr 48692) | Trials (sr 48692) | Recent Studies (post-2010) (sr 48692) | Studies (quinazolines) | Trials (quinazolines) | Recent Studies (post-2010) (quinazolines) |
|---|---|---|---|---|---|
| 203 | 3 | 36 | 19,235 | 2,417 | 8,835 |
| Protein | Taxonomy | sr 48692 (IC50) | quinazolines (IC50) |
|---|---|---|---|
| Epidermal growth factor receptor | Homo sapiens (human) | 0.027 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chan, DC; Jensen, RT; Mantey, SA; Moody, TW; Moreno, P | 1 |
1 other study(ies) available for sr 48692 and quinazolines
| Article | Year |
|---|---|
SR48692 inhibits non-small cell lung cancer proliferation in an EGF receptor-dependent manner.
Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Proliferation; Drug Screening Assays, Antitumor; ErbB Receptors; Extracellular Signal-Regulated MAP Kinases; Gefitinib; Gene Knockdown Techniques; Humans; Lung Neoplasms; Phosphorylation; Protein Processing, Post-Translational; Pyrazoles; Quinazolines; Quinolines; Receptors, Neurotensin; RNA, Small Interfering; Transcriptional Activation; Transforming Growth Factor alpha | 2014 |